Imperative Care Initiates CLEAR-IT Clinical Study to Address Critical Gaps in Clinical Standards for Peripheral Thromboembolism

Company Announces First Patient Enrolled in CLEAR-IT Study Evaluating Symphony and Prodigy Thrombectomy Systems for Vascular Disease

Excerpt from the Press Release:

CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc., a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the enrollment of the first patient in the CLEAR-IT Study, a prospective, observational clinical study evaluating the performance of its Symphony^® and Prodigy^® Thrombectomy Systems. This study aims to advance the development of meaningful clinical standards for the treatment of peripheral thromboembolic diseases.

“The CLEAR-IT Study underscores Imperative Care’s commitment to advancing meaningful innovation grounded in rigorous clinical science to improve patient outcomes and address the unmet needs in peripheral thromboembolism,” said Emir Deljkich, Senior Vice President of Clinical Affairs. “Just as robust clinical data from the Imperative Trial has helped establish new standards of care in acute ischemic stroke, we believe the same level of scientific rigor is essential to advance the peripheral thromboembolism space. This study represents a critical step in building clinical evidence to support large-bore, vacuum-generated aspiration thrombectomy for venous thromboembolism, as well as the evaluation of novel device designs for arterial thromboembolism.”

Peripheral thromboembolic conditions, including pulmonary embolism (PE), peripheral venous thrombosis, and peripheral arterial thrombosis, can pose serious risks for patients and often require endovascular thrombectomy.

Click the button below to read the entire Press Release:

Continue Reading The Press Release